- Investing.com
Metrics to compare | ILA | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipILAPeersSector | |
|---|---|---|---|---|
P/E Ratio | −13.2x | −7.2x | −0.4x | |
PEG Ratio | 0.22 | −0.12 | 0.00 | |
Price/Book | 9.7x | 4.2x | 2.6x | |
Price / LTM Sales | 460.6x | 10.8x | 3.1x | |
Upside (Analyst Target) | 263.6% | 104.7% | 49.0% | |
Fair Value Upside | Unlock | 17.5% | 7.0% | Unlock |
Island Pharmaceuticals Limited, a drug repurposing company, focuses on the development of antiviral therapeutics for infectious diseases in Australia and the United States. The company’s lead product candidate is ISLA-101, a drug which is in second clinical-stage for the prevention and treatment of dengue fever and other mosquito vector borne diseases; and Galidesivir, a spectrum antiviral candidate with the potential to address multiple high-priority RNA virus threats. Island Pharmaceuticals Limited was founded in 2017 and is based in Hawthorn East, Australia.